Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers.
作者信息
Fusco Nicola, Malapelle Umberto, Criscitiello Carmen
机构信息
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
Front Mol Biosci. 2023 Jan 4;9:1117323. doi: 10.3389/fmolb.2022.1117323. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers.社论：2022年乳腺癌的诊断与治疗：新型分子生物标志物的兴起
Front Mol Biosci. 2023 Jan 4;9:1117323. doi: 10.3389/fmolb.2022.1117323. eCollection 2022.
2
The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine.在精准医学时代，病理学家的角色从形态学家转变为分子病理学家。
Breast J. 2020 Jan;26(1):27-34. doi: 10.1111/tbj.13728. Epub 2019 Dec 25.
3
Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer.乳腺癌靶向治疗时代的预测性诊断病理学
Curr Drug Targets. 2017;18(1):4-12. doi: 10.2174/1389450116666150203121218.
4
Validated biomarkers: The key to precision treatment in patients with breast cancer.经过验证的生物标志物：乳腺癌患者精准治疗的关键。
Breast. 2016 Oct;29:192-201. doi: 10.1016/j.breast.2016.07.009. Epub 2016 Aug 9.
5
Predictive biomarkers for personalized medicine in breast cancer.乳腺癌个体化医学的预测生物标志物。
Cancer Lett. 2022 Oct 1;545:215828. doi: 10.1016/j.canlet.2022.215828. Epub 2022 Jul 16.
6
Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.乳腺癌患者的病理诊断：从传统临床病理模式向“精准”癌症治疗的演变
Biotech Histochem. 2017;92(3):175-200. doi: 10.1080/10520295.2017.1290276. Epub 2017 Mar 20.
7
Molecular Imaging and Precision Medicine in Breast Cancer.乳腺癌中的分子成像与精准医学
PET Clin. 2017 Jan;12(1):39-51. doi: 10.1016/j.cpet.2016.08.001. Epub 2016 Oct 4.
8
Precision Medicine in Breast Cancer.乳腺癌中的精准医学
Radiol Technol. 2017 Mar;88(4):401M-421M.
9
Current Biomarkers for Precision Medicine in Breast Cancer.乳腺癌精准医学的当前生物标志物
Adv Exp Med Biol. 2021;1187:363-379. doi: 10.1007/978-981-32-9620-6_18.
10
Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era.精准医学时代的乳腺癌诊治
Methods Mol Biol. 2020;2204:53-61. doi: 10.1007/978-1-0716-0904-0_5.
引用本文的文献
1
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.早期乳腺癌风险评估的进展：从组织病理学到分子技术
Cancers (Basel). 2023 Nov 15;15(22):5430. doi: 10.3390/cancers15225430.
2
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.符合 2023 年 ASCO/CAP 更新和 2023 年 ESMO 关于 HER2 低乳腺癌共识声明的 HER2 检测标准化病理报告。
Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28.
本文引用的文献
1
Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for Testing in HR+/HER2- Breast Cancer.下一代测序和 RT-PCR 在福尔马林固定石蜡包埋肿瘤组织中用于 HR+/HER2- 乳腺癌检测的分析性能。
Cells. 2022 Nov 9;11(22):3545. doi: 10.3390/cells11223545.
2
Artificial Intelligence in Breast Cancer Screening and Diagnosis.人工智能在乳腺癌筛查与诊断中的应用
Cureus. 2022 Oct 15;14(10):e30318. doi: 10.7759/cureus.30318. eCollection 2022 Oct.
3
The evolving landscape of anatomic pathology.解剖病理学的发展现状。
Crit Rev Oncol Hematol. 2022 Oct;178:103776. doi: 10.1016/j.critrevonc.2022.103776. Epub 2022 Aug 5.
4
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.转移性乳腺癌系统治疗的生物标志物：ASCO 指南更新。
J Clin Oncol. 2022 Sep 20;40(27):3205-3221. doi: 10.1200/JCO.22.01063. Epub 2022 Jun 27.
5
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.早期乳腺癌中 ERBB2-低表达的预后和生物学意义。
JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286.
6
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.HER2低表达、超低表达及新型补充生物标志物：拓展乳腺癌HER2阳性的范围
Front Mol Biosci. 2022 Mar 15;9:834651. doi: 10.3389/fmolb.2022.834651. eCollection 2022.
7
Health-Related Suffering and Palliative Care in Breast Cancer.乳腺癌中的健康相关痛苦与姑息治疗
Curr Breast Cancer Rep. 2021;13(4):241-246. doi: 10.1007/s12609-021-00431-1. Epub 2021 Nov 16.
8
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.乳腺癌中雌激素受体低表达状态的评估：对病理学家和肿瘤学家的意义。
Histol Histopathol. 2021 Dec;36(12):1235-1245. doi: 10.14670/HH-18-376. Epub 2021 Sep 29.
9
Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology.乳腺癌患者的免疫治疗：当前肿瘤学中可用生物标志物的应用焦点。
Anticancer Agents Med Chem. 2022;22(4):787-800. doi: 10.2174/1871520621666210706144112.
10
Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies.乳腺癌幸存者的生活质量干预：靶向康复策略的最新进展
Anticancer Agents Med Chem. 2022;22(4):801-810. doi: 10.2174/1871520621666210609095602.
Zotero 插件